The progressive supranuclear palsy (PSP) therapies market, is a
Posted December 23, 2021
The exact cause of this rare disorder, which affects 5-17 in 100,000 people, is unknown; however, a complex interplay between different risk factors, including age, genetics and environment, is likely to contribute to the onset of this rare tauopathy
London
&n...